Angelini Pharma S.p.A. (“Angelini Pharma”), international pharmaceutical company and part of Angelini Industries, announces the completion of its acquisition of Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX). Catalyst is now part of Angelini Pharma, integrating Catalyst’s portfolio and commercial infrastructure with Angelini Pharma’s expertise and products in Brain Health. The transaction provides the participation of funds managed by Blackstone, that will invest 1 billion euros in preferred equity, subject to customary regulatory clearances. CDP Equity has approved to invest around 1 billion euros through a capital increase to acquire a 23.5 per cent stake in the common equity of Angelini Pharma.
Read the full article: Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2026/07/16/3328252/0/en/angelini-pharma-completes-acquisition-of-catalyst-pharmaceuticals.html